Zhiyong, Ji,
Yeping, Ling,
Pingbo, Chen,
Meng, Yuxiao,
Xu, Shancai,
Wu, Pei,
Wang, Chunlei,
Ilyasova, Tatiana,
Sun, Bowen,
Shi, Huaizhang (2023)
in reasonably selected patients. The perioperative
safety is within the
acceptable range. Before 51 days
Malieyskiy, O.,
Mykola, A.,
Nataliya, Z.,
Bolshova, E.V.,
Senatorova, G.,
Oroszlan, G.,
Skorodok, J.,
Peterkova, V.,
Nataliya, C.,
Sorokman, T.,
Yang, S.,
Lee, J.E.,
Muzsnai, A.,
Hwang, J.S.,
Lee, S.Y.,
Choi, Y.J.,
Ji, H.J.,
Woo, J.,
Sung, Y.C. (2018) was observed in this study.
Safety profiles were comparable across the treatment groups and with Genotropin
Zhang, G.,
Zhu, Y.,
Ling, Y.,
Chen, P.,
Dai, J.,
Wang, Ch.,
Xu, Sh.,
Shumadalova, A.,
Shi, H. (2022) as modified treatment in cerebral ischemia (mTICI) 2b−3 after endovascular therapy.
Safety variables included